| Summary: | Background: Candidiasis is an opportunistic and
endogenous infection of Candida sp. which often come
against the immunocompromise host. Candidiasis become
the most opportunistic infection in people with
HIV/AIDS. Invasive candidiasis become the fourth
highest nosocomial infection in the United States and
other developed countries. Itraconazole and
ketoconazole are antifungal agents that widely used for
treatment of candidiasis. However, irrational use of
antifungal treatment cause the appearance of strains of
Candida sp. which resistant to itraconazole and
ketoconazole. This resistance trigger the need for new
antifungal agents which more effective. Phenantroline 1
compound is new compound derivated from 1,10-
phenanthroline. 1,10-phenanthroline has been shown to
have antifungal activity against Candida sp. There are
no data of antifungal potention of phenantroline 1
compound against strain of Candida sp. which resistant
to itraconazole and ketoconazole.
Objective: The objective of this study is to determine
the antifungal potention of phenanthroline 1 compounds
and minimal inhibitory concentration of these compounds
against strains of Candida sp. which resistant to
itraconazole and ketoconazole.
Method: This study was conducted with experimental
descriptive design, using microbroth dilution method.
Result: The antifungal potention of phenanthroline 1
compound against strain of Candida sp. which resistant
to itraconazole and ketoconazole are indicated by
minimal inhibitory concentration 3.175 μg/ml.
Conclusion: Phenanthroline 1 compound has antifungal
potention against strain of Candida sp. which resistant
to itraconazole and ketoconazole, but the mechanism of
action is still unknown.
|
|---|